Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
10.1080/14737167.2024.2319607
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Taylor & Francis
2024
|
| Online Access: | https://scholarbank.nus.edu.sg/handle/10635/249007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | National University of Singapore |
| id |
sg-nus-scholar.10635-249007 |
|---|---|
| record_format |
dspace |
| spelling |
sg-nus-scholar.10635-2490072024-11-10T09:52:48Z Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore Cheng Ean Chee Jasmeet Singh Khara John Cheong Jek Fong Sivabalan Sivanesan Jian Yi Choy Meibo Hu Amrita Viswambaram Han Chong Toh MEDICINE 10.1080/14737167.2024.2319607 Expert Review of Pharmacoeconomics & Outcomes Research 24 5 631-641 2024-06-24T06:22:45Z 2024-06-24T06:22:45Z 2024-05-22 Article Cheng Ean Chee, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Jian Yi Choy, Meibo Hu, Amrita Viswambaram, Han Chong Toh (2024-05-22). Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research 24 (5) : 631-641. ScholarBank@NUS Repository. https://doi.org/10.1080/14737167.2024.2319607 1473-7167 https://scholarbank.nus.edu.sg/handle/10635/249007 Taylor & Francis Taylor & Francis |
| institution |
National University of Singapore |
| building |
NUS Library |
| continent |
Asia |
| country |
Singapore Singapore |
| content_provider |
NUS Library |
| collection |
ScholarBank@NUS |
| description |
10.1080/14737167.2024.2319607 |
| author2 |
MEDICINE |
| author_facet |
MEDICINE Cheng Ean Chee Jasmeet Singh Khara John Cheong Jek Fong Sivabalan Sivanesan Jian Yi Choy Meibo Hu Amrita Viswambaram Han Chong Toh |
| format |
Article |
| author |
Cheng Ean Chee Jasmeet Singh Khara John Cheong Jek Fong Sivabalan Sivanesan Jian Yi Choy Meibo Hu Amrita Viswambaram Han Chong Toh |
| spellingShingle |
Cheng Ean Chee Jasmeet Singh Khara John Cheong Jek Fong Sivabalan Sivanesan Jian Yi Choy Meibo Hu Amrita Viswambaram Han Chong Toh Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore |
| author_sort |
Cheng Ean Chee |
| title |
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore |
| title_short |
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore |
| title_full |
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore |
| title_fullStr |
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore |
| title_full_unstemmed |
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore |
| title_sort |
cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in singapore |
| publisher |
Taylor & Francis |
| publishDate |
2024 |
| url |
https://scholarbank.nus.edu.sg/handle/10635/249007 |
| _version_ |
1821224968770289664 |